vs
Side-by-side financial comparison of Commercial Bancgroup, Inc. (CBK) and FENNEC PHARMACEUTICALS INC. (FENC). Click either name above to swap in a different company.
Commercial Bancgroup, Inc. is the larger business by last-quarter revenue ($23.1M vs $13.8M, roughly 1.7× FENNEC PHARMACEUTICALS INC.). Commercial Bancgroup, Inc. runs the higher net margin — 41.3% vs -34.7%, a 76.1% gap on every dollar of revenue.
Commercial Bancgroup, Inc.CBKEarnings & Financial Report
Commercial Bancgroup, Inc. operates as a U.S. regional bank holding company that provides a full suite of retail and commercial banking products and services to individual consumers, small and medium-sized businesses, and local institutional clients. Its core offerings include deposit accounts, lending solutions, wealth management, and tailored financial advisory services for regional markets.
Fennec Pharmaceuticals Inc. is a biopharmaceutical firm focused on developing and commercializing therapies to reduce treatment-related side effects in pediatric cancer patients. Its lead product targets chemotherapy-induced ototoxicity, with core North American markets serving oncology providers and vulnerable pediatric patient groups.
CBK vs FENC — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $23.1M | $13.8M |
| Net Profit | $9.5M | $-4.8M |
| Gross Margin | — | — |
| Operating Margin | — | -18.5% |
| Net Margin | 41.3% | -34.7% |
| Revenue YoY | — | 73.8% |
| Net Profit YoY | 9.7% | -141.1% |
| EPS (diluted) | $0.69 | $-0.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $23.1M | — | ||
| Q4 25 | $23.5M | $13.8M | ||
| Q3 25 | $22.8M | $12.5M | ||
| Q2 25 | — | $9.7M | ||
| Q1 25 | — | $8.8M | ||
| Q4 24 | — | $7.9M | ||
| Q3 24 | — | $7.0M | ||
| Q2 24 | — | $7.3M |
| Q1 26 | $9.5M | — | ||
| Q4 25 | $9.9M | $-4.8M | ||
| Q3 25 | $9.5M | $-638.0K | ||
| Q2 25 | — | $-3.2M | ||
| Q1 25 | — | $-1.2M | ||
| Q4 24 | — | $-2.0M | ||
| Q3 24 | — | $-5.7M | ||
| Q2 24 | — | $-5.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | -18.5% | ||
| Q3 25 | 53.8% | -1.5% | ||
| Q2 25 | — | -28.3% | ||
| Q1 25 | — | -9.2% | ||
| Q4 24 | — | -11.8% | ||
| Q3 24 | — | -74.6% | ||
| Q2 24 | — | -69.4% |
| Q1 26 | 41.3% | — | ||
| Q4 25 | 42.2% | -34.7% | ||
| Q3 25 | 41.4% | -5.1% | ||
| Q2 25 | — | -32.7% | ||
| Q1 25 | — | -13.3% | ||
| Q4 24 | — | -25.0% | ||
| Q3 24 | — | -82.2% | ||
| Q2 24 | — | -76.5% |
| Q1 26 | $0.69 | — | ||
| Q4 25 | $0.72 | $-0.17 | ||
| Q3 25 | $0.77 | $-0.02 | ||
| Q2 25 | — | $-0.11 | ||
| Q1 25 | — | $-0.04 | ||
| Q4 24 | — | $-0.02 | ||
| Q3 24 | — | $-0.21 | ||
| Q2 24 | — | $-0.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $36.8M |
| Total DebtLower is stronger | $118.2M | — |
| Stockholders' EquityBook value | — | $35.5M |
| Total Assets | $2.3B | $70.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $36.8M | ||
| Q3 25 | $154.8M | $21.9M | ||
| Q2 25 | — | $18.7M | ||
| Q1 25 | — | $22.7M | ||
| Q4 24 | — | $26.6M | ||
| Q3 24 | — | $40.3M | ||
| Q2 24 | — | $43.1M |
| Q1 26 | $118.2M | — | ||
| Q4 25 | $166.8M | — | ||
| Q3 25 | $100.1M | $19.4M | ||
| Q2 25 | — | $19.4M | ||
| Q1 25 | — | $19.4M | ||
| Q4 24 | — | $19.3M | ||
| Q3 24 | — | $32.1M | ||
| Q2 24 | — | $31.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | $35.5M | ||
| Q3 25 | $245.2M | $-4.5M | ||
| Q2 25 | — | $-7.5M | ||
| Q1 25 | — | $-5.9M | ||
| Q4 24 | — | $-5.9M | ||
| Q3 24 | — | $-5.2M | ||
| Q2 24 | — | $-1.4M |
| Q1 26 | $2.3B | — | ||
| Q4 25 | $2.3B | $70.6M | ||
| Q3 25 | $2.2B | $49.3M | ||
| Q2 25 | — | $44.9M | ||
| Q1 25 | — | $46.4M | ||
| Q4 24 | — | $44.9M | ||
| Q3 24 | — | $58.9M | ||
| Q2 24 | — | $63.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.41× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-6.0M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $-6.0M | ||
| Q3 25 | $28.0M | $1.5M | ||
| Q2 25 | — | $-3.7M | ||
| Q1 25 | — | $-4.3M | ||
| Q4 24 | — | $-1.5M | ||
| Q3 24 | — | $-2.2M | ||
| Q2 24 | — | $-8.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $26.5M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 115.8% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 6.7% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 2.96× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CBK
| Net Interest Income | $20.5M | 89% |
| Noninterest Income | $2.6M | 11% |
FENC
Segment breakdown not available.
